As observed in human whole blood in vitro (Fig. 2B), treatment of tumor-bearing mice with a single dose of mTAK-500 resulted in a dose-dependent increase in IP-10, CCL2 (MCP-1), IFN-α, TNF-α, IL-6, and IFN-γ levels in vivo with an average maximum increase of 205-, 813-, 304-, 377-, 4,061-, and 268-fold, respectively (Fig. 3B). The gene discussed is CXCL10; the disease is neoplasm.